目的：探讨结肠癌细胞膜包裹的铜基金属有机框架（MOF@CCM）的DC激活和促进血管新生的潜力。方法：首先构建 1，3，5-苯三甲酸铜（Ⅱ）铜基金属有机框架（HKUST-1），在其外层包覆结肠癌CT26细胞膜，获得MOF@CCM，对其进行物理表征。 用CCK-8法研究MOF@CCM的生物相容性，流式细胞术分析MOF@CCM对DC2.4成熟比例的影响，以验证MOF@CCM激活免疫 细胞的潜力。通过血管生成实验验证MOF@CCM促人脐静脉内皮细胞（HUVEC）形成血管的能力。结果：成功制备了MOF@CCM， 透射电镜观察显示其形状近似圆形，具有明显的核壳结构。MOF@CCM的平均粒径为（150.5±7.89） nm，平均Zeta 电位为–（5.12± 1.67） mV。体外实验结果显示，与对照组相比，MOF@CCM能够显著提高DC2.4成熟的比例（P<0.01）。此外，MOF和MOF@CCM 均能促进HUVEC形成管状结构（P<0.05或P<0.01），且细胞膜修饰对MOF的促血管新生作用没有影响。结论：制备的MOF@CCM 在所使用的剂量下具有良好的细胞相容性，能够显著促进DC2.4的成熟和促进HUVEC血管生成，有望成为抗结肠癌和促进组织修 复的双功能治疗平台。

Objective: To explore the potential of colon cancer cell membrane-coated copper-based metal-organic frameworks (MOF@CCM) in anti-tumor activities and promotion of tissue healing. Methods: Copper (Ⅱ) 1, 3, 5-benzenetricarboxylate copperbased metal-organic framework (HKUST-1) was constructed, and coated with colon cancer cell CT26 membrane on its outer layer to obtain MOF@CCM, which was physically characterized. The biocompatibility of MOF@CCM was determined by CCK-8 assay, and the effect of MOF@CCM on the proportion of DC2.4 maturation was analyzed by flow cytometry to verify the potential of MOF@CCM in activating immune cells. Angiogenesis experiments was used to verify the potential of MOF@CCM in promoting HUVEC to form blood vessels. Results: MOF@CCM was successfully synthesized. Transmission electron microscopy showed that its shape was approximately circular and had an obvious core-shell structure. The average particle size of MOF@CCM was (150.5±7.89) nm, and the average Zeta potential was -(5.12±1.67) mV. The results of in vitro experiments showed that compared with the control group, MOF@CCM could significantly increase the proportion of DC2.4 maturation ( PP<0.05 or P<0.01), and cell membrane modification had no significant effect on the pro-neovascularization effect of MOF. Conclusion: The synthesized MOF@CCM has good cell compatibility at the dose used and can significantly promote the maturation of DC2.4 cells and HUVEC angiogenesis. It is expected to become a bifunctional treatment platform for anti-colon cancer treatment and tissue repair promotion.

国家自然科学基金（No. 82072051）